Summary

Introduction to Europe Non-Invasive Prenatal Testing (NIPT) Market

The Europe NIPT market was valued at $859.2 million in 2023 and is expected to reach $3,230.6 million by 2033, registering a CAGR of 14.16% during the forecast period 2023-2033. The European NIPT market is primarily driven by the implementation of favorable guidelines, the inclusion of screening procedures in reimbursement policies, ongoing advancements in technology, expanding commercial opportunities across the region, and the growing preference for non-invasive testing methods.

Market Introduction

The market for non-invasive prenatal testing (NIPT) in Europe has grown significantly in recent years due to the development of genomic technologies and the increased need for prenatal screening techniques that are safer and more accurate. The ground-breaking method known as NIPT looks for chromosomal abnormalities such Patau syndrome, Edwards syndrome, and Down syndrome by analyzing cell-free fetal DNA in the mother's bloodstream. It is a preferred choice for pregnant parents and medical professionals because of its non-invasive nature, which removes the hazards connected to conventional diagnostic techniques like amniocentesis.

Favorable regulatory frameworks, growing patient and healthcare professional knowledge, and the incorporation of NIPT into both public and private healthcare systems all contribute to the market's growth. Its popularity has been further accelerated by reimbursement regulations in a number of European nations, especially in areas with established prenatal care infrastructure.

The market's major players are concentrating on technology advancements to improve the NIPT services' affordability, accessibility, and accuracy. Furthermore, the necessity for trustworthy prenatal screening methods has increased due to the tendency of late pregnancies and the aging of mothers. Consequently, the NIPT market in Europe is expected to increase steadily, contributing to better maternal and fetal healthcare outcomes throughout the area and facilitating informed decision-making.

Market Segmentation:

Segmentation 1: by Application
• Trisomy Detection
• Microdeletion Detection
• Sex Chromosome Aneuploidy Detection
• Others

Segmentation 2: by End User
• Hospitals
• Diagnostic Laboratories
• Others

Segmentation 3: by Platform
• NGS
• PCR
• Others

Segmentation 4: by Method
• cfDNA
• FCMB

Segmentation 5: by Country
• France
• Germany
• Italy
• Spain
• U.K.
• Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe NIPT market (by application) has been segmented into detailed segments of the application of NIPT based on applications, including trisomy detection, microdeletion detection, sex chromosome aneuploidy detection, and others.

Growth/Marketing Strategy: Constant advancement and innovation to enhance performance and efficiency can enabled prominent players to command premium prices while maintaining growth in revenue and volume.

Competitive Strategy: Key players in the Europe NIPT market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe NIPT market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

• F. Hoffmann-La Roche Ltd
• CENTOGENE N.V.
• Yourgene Health
• Eurofins Scientific SE

ページTOPに戻る

Table of Contents

Executive Summary
Scope and Definition
1 Markets
1.1 Trends: Current and Future Impact Assessment
1.1.1 Increasing Strategic Partnerships and Alliances between Market Players
1.1.2 Expanding Applications in NIPT Products
1.2 Supply Chain Overview
1.3 Research and Development Review
1.3.1 Patent Filing Trend (by Country, Year)
1.4 Regulatory Landscape
1.4.1 Regulatory Scenario in the U.K.
1.4.2 Regulatory Scenario in Germany
1.4.3 Regulatory Scenario in France
1.4.4 Regulatory Scenario in Spain
1.4.5 Regulatory Scenario in Italy
1.4.6 Regulatory Scenario in the Netherlands
1.5 Reimbursement Scenario
1.6 Market Dynamics Overview
1.6.1 Market Drivers
1.6.1.1 High Incidence of Genetic Disorders
1.6.1.2 Rising Maternal Age
1.6.1.3 Increasing Number of Reimbursement Policies toward Genetic Coverage
1.6.1.4 Increased Emphasis on Early Detection and Prevention
1.6.2 Market Restraints
1.6.2.1 Stringent Regulatory Guidelines and Ethical Hurdles
1.6.2.2 Lack of Awareness Regarding NIPT
1.6.2.3 Limitations and Considerations in Non-Invasive Prenatal Testing
1.6.3 Market Opportunities
1.6.3.1 Increasing Focus on Non-Invasive Pre-Implantation Genetic Testing (niPGT)
2 Regions
2.1 Drivers and Restraints
2.2 Regional Summary
2.3 Europe
2.3.1 Regional Overview
2.3.2 Driving Factors for Market Growth
2.3.3 Factors Challenging the Market
2.3.4 Application
2.3.5 Product
2.3.6 France
2.3.7 Germany
2.3.8 U.K.
2.3.9 Spain
2.3.10 Italy
2.3.11 Rest-of-Europe
3 Markets - Competitive Benchmarking & Company Profiles
3.1 Competitive Landscape
3.1.1 F. Hoffmann-La Roche Ltd
3.1.1.1 Overview
3.1.1.2 Product Portfolio
3.1.1.3 Top Competitors
3.1.1.4 Target Customers
3.1.1.5 Key Personnel
3.1.1.6 Analyst View
3.1.2 CENTOGENE N.V.
3.1.2.1 Overview
3.1.2.2 Product Portfolio
3.1.2.3 Top Competitors
3.1.2.4 Target Customers
3.1.2.5 Key Personnel
3.1.2.6 Analyst View
3.1.3 Yourgene Health
3.1.3.1 Overview
3.1.3.2 Product Portfolio
3.1.3.3 Top Competitors
3.1.3.4 Target Customers
3.1.3.5 Key Personnel
3.1.3.6 Analyst View
3.1.4 Eurofins Scientific SE
3.1.4.1 Overview
3.1.4.2 Product Portfolio
3.1.4.3 Top Competitors
3.1.4.4 Target Customers
3.1.4.5 Key Personnel
3.1.4.6 Analyst View
4 Research Methodology
4.1 Data Sources
4.1.1 Primary Data Sources
4.1.2 Secondary Data Sources
4.1.3 Data Triangulation
4.2 Market Estimation and Forecast
List of Figures
Figure 1: Non-Invasive Prenatal Testing Market (by Region), $Million, 2022, 2026, and 2033
Figure 2: Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022, 2026, and 2033
Figure 3: Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022, 2026, and 2033
Figure 4: Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022, 2026, and 2033
Figure 5: Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022, 2026, and 2033
Figure 6: Non-Invasive Prenatal Testing Market, Recent Developments, 2023
Figure 7: Supply Chain of NIPT Market
Figure 8: NIPT Market, Patent Analysis, (by Country), January 2020-December 2023
Figure 9: NIPT Market, Patent Analysis, (by Year), January 2020-December 2023
Figure 10: Reimbursement Scenario in Major Countries of the Europe NIPT Market
Figure 11: Impact Analysis of Market Navigating Factors, 2022-2033
Figure 12: Births with Trisomies per 100,000 Live Births in Europe Region, 2000-2021
Figure 13: Age of Mother at Childbirth over the Years
Figure 14: Reimbursement Scenario in Major Countries
Figure 15: Number of Tests Processed by Natera, Inc., 2018-2020
Figure 16: Positives from Data of 75,000 NIPT Tests Showing False Positives
Figure 17: Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
Figure 18: Europe Non-Invasive Prenatal Testing Market, $Million, 2023-2033
Figure 19: France Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
Figure 20: France Non-Invasive Prenatal Testing Market, $Million, 2023-2033
Figure 21: Germany Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
Figure 22: Germany Non-Invasive Prenatal Testing Market, $Million, 2023-2033
Figure 23: U.K. Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
Figure 24: U.K. Non-Invasive Prenatal Testing Market, $Million, 2022-2033
Figure 25: Spain Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
Figure 26: Spain Non-Invasive Prenatal Testing Market, $Million, 2022-2033
Figure 27: Italy Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
Figure 28: Italy Non-Invasive Prenatal Testing Market, $Million, 2022-2033
Figure 29: Rest-of-Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
Figure 30: Rest-of-Europe Non-Invasive Prenatal Testing Market, $Million, 2022-2033
Figure 31: Share of Strategic Initiatives
Figure 32: Data Triangulation
Figure 33: Top-Down and Bottom-Up
Figure 34: Assumptions and Limitations
List of Tables
Table 1: Market Snapshot
Table 2: Non-Invasive Prenatal Testing Market, Opportunities
Table 3: Key Companies’ Partnerships and Alliances
Table 4: NIPT Tests in the NIPT Market and their Corresponding Applications
Table 5: Risk of Chromosomal Abnormality w.r.t Maternal Age
Table 6: Non-Invasive Prenatal Testing Market (by Region), Thousands Units, 2022-2033
Table 7: Non-Invasive Prenatal Testing Market (by Region), $Million, 2022-2033
Table 8: Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
Table 9: Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
Table 10: Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
Table 11: Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
Table 12: France Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
Table 13: France Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
Table 14: France Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
Table 15: France Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
Table 16: Germany Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
Table 17: Germany Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
Table 18: Germany Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
Table 19: Germany Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
Table 20: U.K. Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
Table 21: U.K. Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
Table 22: U.K. Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
Table 23: U.K. Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
Table 24: Spain Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
Table 25: Spain Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
Table 26: Spain Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
Table 27: Spain Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
Table 28: Italy Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
Table 29: Italy Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
Table 30: Italy Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
Table 31: Italy Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
Table 32: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
Table 33: Rest-of-Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
Table 34: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
Table 35: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
Table 36: Market Share (2022)

Press Release